c-myc amplifications in primary breast carcinomas and their local recurrences

Journal of Clinical Pathology

Volumn 59, Issue 4, 2006, Pages 424-428

  Aulmann, S ^a   Adler, N ^a   Rom, J ^a   Helmchen, B ^a   Schirmacher, P ^a   Sinn, H P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE NUMBER; HUMAN; HUMAN TISSUE; ONCOGENE C MYC; PRIORITY JOURNAL; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; GENE AMPLIFICATION; GENES, MYC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 33645653342     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.029264     Document Type: Article

References (34)

1. Legorreta AP, Chernicoff HO, Trinh JB, et al. Diagnosis, clinical staging, and treatment of breast cancer: a retrospective multiyear study of a large controlled population. Am J Clin Oncol 2004;27:185-90.
2. Fredriksson I, Liljegren G, Arnesson LG, et al. Time trends in the results of breast conservation in 4694 women. Eur J Cancer 2001;37:1537-44.
3. Huston TL, Simmons RM. Locally recurrent breast cancer after conservation therapy. Am J Surg 2005;189:229-35.
4. Voogd AC, van Tienhoven G, Peterse HL, et al. Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients. Dutch Study Group on Local Recurrence after Breast Conservation (BORST). Cancer 1999;85:437-46.
5. Haffty BG, Hauser A, Choi DH, et al. Molecular markers for prognosis after isolated postmastectomy chest wall recurrence. Cancer 2004;100:252-63.
6. Sinn HP, Anton HW, Magener A, et al. Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy. Eur J Cancer 1998;34:646-53.
7. Isaacs C, Stearns V, Hayes DF. New prognostic factors for breast cancer recurrence. Semin Oncol 2001;28:53-67.
8. Le MG, Arriagada R, Spielmann M, et al. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer 2002;94:2813-20.
9. Engel J, Eckel R, Aydemir U, et al. Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 2003;55:1186-95.
10. Fredriksson I, Liljegren G, Palm-Sjovall M, et al. Risk factors for local recurrence after breast-conserving surgery. Br J Surg 2003;90:1093-102.
11. Ellis IO, Schnitt SJ, Sastre-Garau X, et al. Invasive breast carcinoma. In:Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs (WHO classification of tumours). Lyon: IARC Press, 2003:13-59.
12. Aulmann S, Bentz M, Sinn HP. C-myc oncogene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2002;74:25-31.
13. Joos S, Falk MH, Lichter P, et al. Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. Hum Mol Genet 1992;1:625-32.
14. Lichter P, Bentz M, Joos S. Detection of chromosomal aberratins by means of molecular cytogenetics: painting of chromosomes and chromosomal subregions and comparative genomic hybridization. Methods Enzymol 1995;254:334-59.
15. Remmele W, Dietz M, Schmidt F, et al. Relation of elastosis to biochemical and immunohistochemical steroid receptor findings, Ki-67 and epidermal growth factor receptor (EGFR) immunostaining in invasive ductal breast cancer. Virchows Arch A Pathol Anat Histopathol 1993;422:319-26.
16. Vicini FA, Kestin L, Huang R, et al. Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer 2003;97:910-19.
17. Nishizaki T, DeVries S, Chew K, et al. Genetic alterations in primary breast cancers and their metastases: direct comparison using modified comparative genomic hybridization. Genes Chromosomes Cancer 1997;19:267-72.
18. Regitnig P, Moser R, Thalhammer M, et al. Microsatellite analysis of breast carcinoma and corresponding local recurrences. J Pathol 2002;198:190-7.
19. Guo QM, Malek RL, Kim S, et al. Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res 2000;60:5922-8.
20. Jamerson MH, Johnson MD, Dickson RB. Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene 2000;19:1065-71.
21. McCormack SJ, Weaver Z, Deming S, et al. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene 1998;16:2755-66.
22. Cardiff RD, Sinn E, Muller W, et al. Transgenic oncogene mice. Tumor phenotype predicts genotype. Am J Pathol 1991;139:495-501.
23. Jager R, Herzer U, Schenkel J, et al. Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene 1997;15:1787-95.
24. Isola J, Chu L, DeVries S, et al. Genetic alterations in ERBB2-amplified breast carcinomas. Clin Cancer Res 1999;5:4140-5.
25. Rummukainen JK, Salminen T, Lundin J, et al. Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest 2001;81:1545-51.
26. Al-Kuroya K, Schraml P, Torhorst J, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004;64:8534-40.
27. Grushko TA, Dignam JJ, Das S, et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 2004;10:499-507.
28. Adem C, Soderberg CL, Hafner K, et al. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer 2004;41:1-11.
29. Fiche M, Avet-Loiseau H, Maugard CM, et al. Gene amplifications detected by fluorescence in situ hybridization in pure intradudal breast carcinomas: relation to morphology, cell proliferation and expression of breast cancer-related genes. Int J Cancer 2000;89:403-10.
30. Naidu R, Wahab NA, Yadav M, et al. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int J Mol Med 2002;9:189-96.
31. Robanus-Maandag EC, Bosch CA, Kristel PM, et al. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol 2003;201:75-82.
32. Sheen JH, Woo JK, Dickson RB. c-Myc alters the DNA damage-induced G2/M arrest in human mammary epithelial cells. Br J Cancer 2003;89:1479-85.
33. Sheen JH, Dickson RB. Overexpression of c-Myc alters G(1)/S arrest following ionizing radiation. Mol Cell Biol 2002;22:1819-33.
34. Venditti M, Iwasiow B, Orr FW, et al. C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. Int J Cancer 2002;99:35-42.